German cohort on Sofosbuvir based therapy for HIV/HCV- and HCV-infection (GECCO) – Patients on opioid substitution therapy (OST) respond as well as non-OST patients
S Christensen, P Ingiliz, D Hüppe, T Lutz, K Simon, K Schewe, C Schwarze-Zander, H Busch, A Baumgarten, G Schmutz, S Mauss · Zeitschrift für Gastroenterologie · 2015 · Heft 08
Bibliografische Angaben
Zusammenfassung
Background: Sofosbuvir (SOF) was approved in Europe in January 2014. However, outcomes of SOF based therapy in patients on OST in comparison to NON-OST were not systematically studied. Here, we present corresponding real-life data on SOF-based treatments from Germany. Methods: Ongoing multicenter cohort on HCV patients who were started on the following HCV treatments: SOF/Ribavirin (RBV), SOF/Daclatasvir (DCV), SOF/Simeprevir (SMV), SOF/PegIFN/RBV and SOF/Ledipasvir (LDV). For the current analysis only patients with GT 1 or GT3 treated with PegIFN/RBV/SOF (12 weeks) or SOF/RBV (24 weeks) were analysed. Results:…
